Advertisement
Amazon
Amazon

Can NK cells maintain the remission of MS?

Natural killer cells from multiple sclerosis patients in remission have properties resembling those of NK type 2 cells, which can favour functional deviation of T cells toward Th2 and prohibit autoimmune effector T cells.

By | March 16, 2001

Multiple sclerosis (MS) is a Th1-mediated autoimmune disease characterised by relapses followed by clinically stable remissions. A new hypothesis suggests that regulatory immune cells may play an active part not only in relapses but also in maintaining the remission of MS. In the Journal of Clinical Investigation (published online ahead of print), Takahashi et al provide the first evidence of a role for natural killer (NK) cells in the remission of MS (J Clin Invest 2001, 107:R23-R29).

Kazuya Takahashi and colleagues examined NK cells in the peripheral blood of 22 patients with MS and found that during remissions these cells were characterized by an elevation of IL-5 mRNA and a decreased expression of IL-12Rβ2 mRNA. Moreover, the NK cells produced larger amounts of IL- 5 than controls after non-specific stimulation.

These features resemble those of NK type 2 cells, which can favour functional deviation of T cells toward Th2 and prohibit autoimmune effector T cells. The NK cells lost the NK2-like property when relapse of MS occurred but regained it after recovery. Targeting NK cells with immunological interventions such as NK bias may benefit patients with MS.

Advertisement
Advertisement
EMD Millipore
EMD Millipore

Popular Now

  1. Antibody Maker Loses License Over Animal Welfare Violations
  2. ORI: Researcher Faked Dozens of Experiments
    The Nutshell ORI: Researcher Faked Dozens of Experiments

    A former scientist at the University of Michigan and the University of Chicago made up more than 70 experiments on heart cells, according to the Office of Research Integrity.

  3. Exploring Emotional Contagion
  4. Immune Defect Detected in Knockout Mice
Advertisement
SomaLogic
SomaLogic
Advertisement
Biosearch Technologies
illumina Corporate
illumina Corporate